Dolutegravir- versus low-dose Efavirenz-based regimen for the initial treatment of HIV-1 infection in Cameroon : week 96 results of the ANRS 12313-NAMSAL trial Kouanfack, C. Sanchez, T. T. Wandji, M. L. Mpoudi-Etame, M. Bassega, P. O. Perrineau, S. Bwenda, T. A. Tata, D. T. Tongo, M. /Varloteaux, Marie Montoyo, A. /Peeters, Martine Reynes, J. Calmy, A. Delaporte, E. NAMSAL ANRS 12313 Study Group 2020 text https://www.documentation.ird.fr/hor/PAR00021143 PAR00021143 Kouanfack C., Sanchez T. T., Wandji M. L., Mpoudi-Etame M., Bassega P. O., Perrineau S., Bwenda T. A., Tata D. T., Tongo M., Varloteaux Marie, Montoyo A., Peeters Martine, Reynes J., Calmy A., Delaporte E., NAMSAL ANRS 12313 Study Group. Dolutegravir- versus low-dose Efavirenz-based regimen for the initial treatment of HIV-1 infection in Cameroon : week 96 results of the ANRS 12313-NAMSAL trial. 2020, 23 (4), 17-18 EN CAMEROUN